نتایج جستجو برای: integrase inhibitors

تعداد نتایج: 191203  

2017
Mayilaadumveettil Nishana Namrata M Nilavar Rupa Kumari Monica Pandey Sathees C Raghavan

Integrase inhibitors are a class of antiretroviral drugs used for the treatment of AIDS that target HIV integrase, an enzyme responsible for integration of viral cDNA into host genome. RAG1, a critical enzyme involved in V(D)J recombination exhibits structural similarity to HIV integrase. We find that two integrase inhibitors, Raltegravir and Elvitegravir, interfered with the physiological func...

Journal: :Acta crystallographica. Section D, Biological crystallography 2001
V Molteni J Greenwald D Rhodes Y Hwang W Kwiatkowski F D Bushman J S Siegel S Choe

Integration of the reverse-transcribed HIV cDNA into the host DNA is a required step in viral replication. The virus-encoded integrase protein catalyzes the initial DNA breaking and joining reactions that mediate cDNA integration. Here, the identification by X-ray crystallography of a small-molecule binding site on the integrase catalytic domain is reported. The small-molecule family studied co...

2012
G Nichols A Mills R Grossberg A Lazzarin F Maggiolo J Molina G Pialoux D Wright M Ait-Khaled J Huang C Vavro B Wynne J Yeo

Journal: :Molecular pharmacology 2006
Elena A Semenova Allison A Johnson Christophe Marchand David A Davis Robert Yarchoan Yves Pommier

Integration is a crucial step in the life cycle of human immunodeficiency virus type 1 (HIV-1); therefore, inhibitors of HIV-1 integrase are candidates for antiretroviral therapy. Two 7-hydroxytropolone derivatives (alpha-hydroxytropolones) were found to inhibit HIV-1 integrase. A structure-activity relationship investigation with several tropolone derivatives from The National Cancer Institute...

Journal: :Journal of virology 2015
Kaitlin Anstett Thibault Mesplede Maureen Oliveira Vincent Cutillas Mark A Wainberg

The new integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) displays limited cross-resistance with older drugs of this class and selects for the R263K substitution in treatment-experienced patients. We performed tissue culture selections with DTG, using viruses resistant to older INSTIs and infectivity and resistance assays, and showed that the presence of the E92Q or N155H substitut...

Journal: :Journal of medicinal chemistry 2008
Vincenzo Summa Alessia Petrocchi Fabio Bonelli Benedetta Crescenzi Monica Donghi Marco Ferrara Fabrizio Fiore Cristina Gardelli Odalys Gonzalez Paz Daria J Hazuda Philip Jones Olaf Kinzel Ralph Laufer Edith Monteagudo Ester Muraglia Emanuela Nizi Federica Orvieto Paola Pace Giovanna Pescatore Rita Scarpelli Kara Stillmock Marc V Witmer Michael Rowley

Human immunodeficiency virus type-1 (HIV-1) integrase is one of the three virally encoded enzymes required for replication and therefore a rational target for chemotherapeutic intervention in the treatment of HIV-1 infection. We report here the discovery of Raltegravir, the first HIV-integrase inhibitor approved by FDA for the treatment of HIV infection. It derives from the evolution of 5,6-dih...

2010
Zhiqi Yin Robert Craigie

The HIV-1 integrase enzyme is essential for integrating the viral DNA into the host chromosome. Infection is aborted in the absence of integration, making integrase an attractive antiviral target. Recently approved inhibitors of integrase bind tightly to integrase assembled in a nucleoprotein complex with the viral DNA ends (intasome), but have only low affinity for free integrase. High-resolut...

Journal: :Current opinion in HIV and AIDS 2009
Anne-Genevieve Marcelin Francesca Ceccherini-Silberstein Carlo-Federico Perno Vincent Calvez

PURPOSE OF REVIEW Understanding the mechanisms that underlie resistance development to novel drugs is essential to a better clinical management of resistant viruses and to prevent further resistance development and spread. RECENT FINDINGS Integrase inhibitors and CCR5 antagonists are the more recent antiretroviral classes developed. The HIV-1 integrase, responsible for the chromosomal integra...

2014
David A Cooper

WHO standard of care for failure of a first regimen, usually 2N(t)RTI's and an NNRTI, consists of a ritonavir-boosted protease inhibitor with a change in N(t)RTI's. Until recently, there was no evidence to support these recommendations which were based on expert opinion. Two large randomized clinical trials, SECOND LINE and EARNEST both showed excellent response rates (>80%) for the WHO standar...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید